Benign prostate hyperplasia
Conditions
Interventions
a silodosin capsule 4 mg twice daily (8 mg/day) for 4 weeks
Sponsors
Department of Urology Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) an IPSS total score of 8 or greater; 2) an IPSS-quality of life (QOL) score of 3 or greater; 3) prostate volume measured by transabdominal or transrectal echography of 20 mL or greater; 4) maximum flow rate (Qmax) by uroflowmetry (UFM) of less than 15 mL/sec at a voiding volume of greater than 100 mL; 5) post-void residual urine volume (PVR) of less than 150 mL; and 6) age of 50 years or older.
Exclusion criteria
Exclusion criteria: Patients currently receiving alpha-blockers, anticholinergic drugs, antidepressants, antianxiety drugs and/or sex hormones, those with suspected prostate cancer, neurovesical dysfunction, bladder stone or active urinary tract infection were excluded. Patients with any serious cardiac complication, renal complication (serum creatinine of 2 mg/dl or greater) or hepatic complication (AST and ALT that are at least double the reference values) were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare patient background and objective findings from PFS performed at baseline and post-treatment between good and poor responders in symptom improvement. | — |
Countries
Japan
Contacts
Public ContactYoshihisa Matsukawa
Nagoya University Graduate School of Medicine Department of Urology
Outcome results
None listed